Live feed08:00:00·35dPRReleasevia QuantisnowiECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE TrialByQuantisnow·Wall Street's wire, on your screen.DTIL· Precision BioSciences Inc.Health Care
